Related Experiment Video
Updated: Jan 7, 2026
Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
Published on: January 28, 2014
Biomarkers
Tianyi Wang1, Yuyue Qiu1, Li Shang1
1Peking Union Medical College Hospital, Beijing, Beijing, China.
Background:
To evaluate the diagnostic efficacy of plasma biomarkers in distinguishing Alzheimer's disease (AD) from a variety of other neurodegenerative dementias, using both SIMOA and Lumipulse as the detection methods for blood biomarker measurement.
Method:
A total of 292 patients were recruited from the Peking Union Medical College Hospital (PUMCH) dementia cohort. The clinical diagnosis of these patients includes Alzheimer's disease (AD), Cerebral amyloid angiopathy (CAA), Creutzfeldt-Jakob disease (CJD), frontotemporal dementia (FTD), hereditary diffuse leukoencephalopathy with spheroids (HDLS), neuronal intranuclear inclusion disease (NIID), normal pressure hydrocephalus (NPH), vascular dementia (VAD) and dementia of undetermined etiology. Plasma biomarkers were measured using SIMOA and Lumipulse commercially available kits.
Result:
Plasma levels of Aβ42/40, pTau181, pTau217, GFAP, and NFL were compared across different clinical diagnostic groups of neurodegenerative diseases in dementia patients. Among these biomarkers, plasma pTau217 showed the most significant difference between AD and other neurodegenerative disease. However, in specific disease groups such as CAA and CJD, plasma pTau217 levels were elevated to levels comparable to those observed in AD. Results for all plasma markers correlated well between SIMOA and Lumipulse, with the strongest correlation observed for plasma pTau217 levels. Based on FDA-approved CSF biomarkers, plasma pTau217 was able to predict CSF Aβ status with high accuracy over 0.9. We also compared plasma biomarker levels differences between CSF A-T-, A+T-, A+T+ groups, no statistical significance was found in Aβ42/40, pTau181, pTau217, GFAP, and NfL biomarkers level between A+T- and A+T+ group, but a trend of plasma pTau217 elevation was shown. Finally, the plasma pTau217 cutoff value was applied to predict Aβ PET and tau PET classifications, in accuracy up to 0.977.
Conclusion:
Plasma pTau217 levels can effectively differentiate AD pathology in dementia patients, with accuracy comparable to that of CSF and PET imaging.
Related Concept Videos
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...